Psoriasis is a chronic inflammatory disease associated with dyslipidemia, cardiovascular events, and mortality. We aimed to assess and compare the effect of treatment of moderate-to-severe psoriasis with adalimumab or phototherapy on vascular inflammation and cardiovascular biomarkers.
P
soriasis is a common chronic Th1/Th17 inflammatory skin disease that affects >125 million people worldwide. 1 Like other diseases of chronic inflammation, it is associated with an increased risk of impairments in lipoprotein metabolism (dyslipidemia and decreased cholesterol efflux capacity), insulin resistance and diabetes mellitus, and major adverse cardiovascular events. [2] [3] [4] [5] The risk of cardiometabolic disease increases with increasing psoriasis severity, is independent of traditional risk factors, and culminates in a lifespan reduction of ≈5 years. 5, 6 The aberrant innate and adaptive immune pathways that drive the pathophysiology of psoriasis are known to also promote insulin resistance, atherosclerosis, and thrombosis. 7 Established and novel inflammatory markers such as C-reactive protein (CRP), tumor necrosis factor (TNF) α, interleukin (IL)-6, and glycoprotein acetylation (GlycA) are increased in psoriasis, 8, 9 associated with skin disease severity 8, 10 and are predictive of future cardiovascular risk in healthy individuals without psoriasis or any other chronic inflammatory condition. 11, 12 Consistent with the translational and epidemiological data linking psoriasis to cardiovascular disease, we and others have demonstrated that patients with psoriasis have increased vascular inflammation (VI), as measured by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), that is equivalent to ≈1 decade of aging, and that increasing skin disease severity is associated with increasing VI independent of traditional cardiovascular risk factors. 10,13 18 F-FDG PET/CT is an attractive surrogate marker, as it predicts cardiovascular events 14 and is highly sensitive to change with short-term (ie, weeks-to-months) treatment with interventions known to lower cardiovascular risk, such as statins and therapeutic lifestyle changes. 15 Psoriasis is a reliable disease to study cardiovascular effects of immune-modulating therapy 13 as it can be treated with a variety of targeted modalities. 7 Adalimumab, a monoclonal antibody that blocks TNF-α, is a standard of care biological therapy used to treat moderate-to-severe psoriasis 16 and is suggested to be associated with a reduction in major cardiovascular events. 17 Narrowband ultraviolet B phototherapy is also highly effective in treating psoriasis but is not associated with clinically significant alterations in systemic immune function. 7 A recently completed randomized trial demonstrated a beneficial effect of a systemic biological anti-inflammatory therapy in reducing rate of myocardial infarction despite minimal change in low-density lipoprotein cholesterol (LDL-C). 18 Phototherapy provides a unique opportunity to compare treatment of psoriasis with a systemic immune-modulating biological therapy (adalimumab) to skin-directed therapy (phototherapy). As such, we conducted a randomized controlled trial, in patients with moderate-to-severe psoriasis, of adalimumab, phototherapy, and placebo to determine the comparative impact of psoriasis treatment with adalimumab and phototherapy on VI measured by 18 F-FDG PET/CT and biomarkers of advanced lipoprotein characterization, glucose metabolism, and inflammation.
METHODS
The data will be made available to other researchers for purposes of reproducing the results, however, materials cannot be made available in view of the concerns about the patient privacy. The study was a multicenter randomized controlled trial designed to enroll 96 patients across 8 centers in the United States with 1:1:1 allocation to adalimumab subcutaneous injections or placebo injections every 2 weeks, or narrowband ultraviolet B phototherapy at baseline (NCT01553058). At week 12, eligible patients entered an open-label extension in which they were treated with adalimumab for 52 weeks (if initially assigned to placebo or phototherapy) or an additional 40 weeks if initially assigned to adalimumab, such that all patients received a total of 52 consecutive weeks of adalimumab (NCT01866592; Figure 1 ). Primary outcome for our study was change in VI, estimated as a target-to-background ratio (TBR) of maximum target aortic activity to blood pool activity by 18 F-FDG PET/CT at week 12 compared with baseline in adalimumab and phototherapy groups compared with placebo. We also conducted a series of analyses of biomarkers
CLINICAL PERSPECTIVE
Inflammation is critical to atherosclerosis. We tested whether anti-inflammatory therapy with anti-tumor necrosis factor agent, adalimumab, reduced vascular inflammation compared with phototherapy and placebo in patients with psoriasis, a chronic inflammatory disease associated with accelerated atherosclerosis. Here, we provide critical data demonstrating significant anti-inflammatory effects of adalimumab in the skin and blood of psoriasis patients without impact on vascular inflammation. Compared with phototherapy and placebo, adalimumab improved skin disease and markers of systemic inflammation. However, it did not change vascular inflammation compared with phototherapy or placebo and was associated with modest impairments in high-density lipoprotein function, providing important information about the impact of targeted inhibition of tumor necrosis factor-α on cardiometabolic biomarkers. This systematic characterization of the effect of anti-tumor necrosis factor therapy on cardiometabolic risk parameters in psoriasis patients provides a reliable framework for future studies to analyze whether targeting other inflammatory pathways to treat psoriasis including anti-interleukin-12/23, anti-interleukin-17 agents, or Phosphodiesterase 4 inhibitors may improve cardiometabolic risk in psoriasis.
of cholesterol, glucose metabolism, and inflammation which were selected based on their known association with psoriasis and cardiovascular disease at baseline, week 4, and week 12.
All participants had to be ≥18 years with a diagnosis of psoriasis for at least 6 months and that of moderate-tosevere psoriasis for at least 2 months, defined as body surface area ≥10% and psoriasis area severity index score of ≥12 at baseline. Patients were excluded if they had any of the following treatments: UVB phototherapy within 14 days of baseline, psoralen-UVA phototherapy within 30 days of baseline, oral psoriasis treatments within 30 days of baseline, biologics within 90 days of baseline (or 180 days for ustekinumab); investigational agents within 30 days or 5 half-lives (whichever is longer) of baseline. Adalimumab (or corresponding placebo) therapy was administered in a double-blind manner as a subcutaneous injection with an initial 80 mg dose at week 0, followed by maintenance doses of 40 mg every other week, starting from week 1 and then continued throughout the study. Narrowband ultraviolet B phototherapy dosing was based on estimated minimal erythema dose and Fitzpatrick skin type using a standardized protocol published by Zanolli and Feldman. 19 18F-FDG PET/CT scans were analyzed to derive TBR values by previously published and validated methods. 10 The extent of 18 F-FDG uptake within the aorta was directly measured by using a dedicated image analysis software (OsiriX MD, Pixmeo SARL, Bernex, Switzerland) to measure VI calculated as TBR. The standardized uptake value (SUV) mean from each of the superior vena cava slices were averaged to produce 1 venous value. To account for background blood activity, SUV max values from each aortic slice were divided by the average venous SUV mean value yielding TBR max values, the primary outcome measure. Patients underwent 18F-FDG PET/CT scans using the standard protocol 20, 21 after an overnight fast. Primary analyses were the comparisons of the treatment effects of adalimumab, phototherapy, and placebo, on the outcome measures using intention-to-treat approach. The changes in TBR max and biomarker values were compared across groups using linear regressions, whereas additional multivariate linear regression models were fitted for TBR max to assess sensitivity to a potential imbalance of covariates, adjusting for clinical and demographic covariates using a backward model building approach. Natural log scale was used for all nonparametric variables. The secondary analyses were the changes in outcome measures from baseline to the end of open-label extension period. The mean changes and proportions were calculated along with their respective 95% confidence intervals (CIs) and were reported as such. Sample size calculations were based on changes in SUV. Using a 2-sided α=0.017 (applying a Bonferroni correction), we determined that 32 patients per arm would provide 82% power to detect the clinically significant change in SUV of 0.1 between groups assuming an anticipated SD of the change in SUV of 0.11 and a dropout rate of 15%.
Study approval was obtained from the Institutional Review Board of the University of Pennsylvania or respective local Institutional Review Board when indicated in accordance with the principles of Declaration of Helsinki. All guidelines for good clinical practice and those set forth by the Belmont Report (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research) were followed. All study participants provided written informed consent. The randomized placebo-controlled trial was overseen by an independent data monitoring committee. The sponsors (National Heart, Lung, and Blood Institute and Abbvie) had no role in the analysis or reporting of the results. Abbvie reviewed the article for compliance purposes. The detailed methods are elaborated in a separate Methods in the Data Supplement.
RESULTS
We screened 179 patients for eligibility and randomized 97 patients to placebo, adalimumab, or phototherapy treatment (1:1:1), with 92 (95%) patients completing the 12-week controlled portion of the study (Figure 2 ). Eighty-one patients entered the open-label adalimum- ab extension portion of the study, of which 58 (72%) completed 52 weeks of adalimumab treatment and had an end of study scan. Nine patients (11%) had an early termination during the extension period and received an early termination scan, thus resulted in 67 (83%) patients being included in the analysis of the open-label extension portion of the study. Study subjects had an average age of 43, were predominantly male (69%), had an average duration of psoriasis of 17 years, and a mean Psoriasis Area and Severity Index of 19. About 10% of patients had a history of psoriatic arthritis, and ≈30% had previously been treated with systemic agents or phototherapy ( Table 1 ). The study groups were well balanced for psoriasis characteristics and cardiovascular risk factors and were similar to populations typically seen in large phase III clinical trials of psoriasis therapeutic agents (Table 1) .
Both adalimumab and phototherapy resulted in substantial improvements in psoriasis severity compared with placebo for physician-reported measures (Table I in the Data Supplement). Patients evaluated during the open-label adalimumab extension period achieved a high rate of skin clearance with 53% of patients being clear or almost clear of their skin disease (Table II in the  Data Supplement) . No statistically significant change was observed in physical activity (as measured using the International Physical Activity Questionnaire metabolic equivalent task minutes) between groups at week 12 or at the end of the extension period. On average, patients reported a reduction in saturated and dietary cholesterol intake at week 12 and end of the openlabel period compared with baseline, but there were no group-level differences.
At baseline mean TBR max values were 1.62, 1.61, and 1.64 in the placebo, adalimumab, and phototherapy groups respectively (Table 1) . Furthermore, the TBR and SUV values at subsequent visits for all 3 groups are noted under Table III in the Data Supplement. There was no difference in change in VI at week 12 in the adalimumab group (change compared with placebo, 0.64%; 95% CI, −5.84% to −7.12%) or the phototherapy group (−1.60%; 95% CI, −6.78% to 3.59%; Table 2 ; Figure 3 ). Analysis within groups demonstrated a statistically significant reduction in VI by −4.09% (95% CI, −7.78% to −0.39%) in the phototherapy treatment arm only. At the end of the extension period, there was a −3.80% reduction in VI compared with the absolute study baseline (week 52 or 64 compared with week 0 for all; 95% CI, −6.40% to −1.19%; Table 3 ). However, there was no change in VI (0.02% difference; 95% CI, −2.85% to 2.90%) during the adalimumab treatment only period comparing end of study assessment to adalimumab baseline (week 52 compared with week 0 for those initially assigned to adalimumab and week 64 CI indicates confidence interval; and TBR, target-to-background ratio. *One sample test (P value). †Statistically significant findings. ‡Difference of differences (P value).
compared with week 12 for those who entered openlabel extension but were initially assigned to placebo/ phototherapy). We evaluated biomarkers of advanced lipoprotein characterization, glucose metabolism, and inflammation (Figure 4 ). During the placebo-controlled period, a reduction in inflammation in the adalimumab group compared with placebo was observed for CRP, TNF-α, IL-6, and GlycA whereas only CRP and IL-6 were reduced in the phototherapy arm (Table 4) . There was no change in lipoprotein characterization or glucose metabolism except for HDL-P which increased in the phototherapy group compared with placebo which was only modestly significant. At the end of the extension period, compared with absolute baseline (week 0 for all), there was no change in total cholesterol, LDL-P, or markers of glucose metabolism, but there was a reduction in efflux and HDL-P. Furthermore, we also observed a reduction in markers of inflammation such as CRP, TNF-α, and GlycA, but an increase in the levels of IL-6 (Table 5) . A similar pattern of biomarker change was observed during the adalimumab treatment only period comparing end of study assessment to adalimumab baseline (week 0 for those initially assigned to adalimumab or week 12 for those initially assigned to placebo or phototherapy; Table 6 ).
DISCUSSION
We conducted a randomized, controlled trial to determine the impact of systemic anti-TNF immune targeted (ie, adalimumab) treatment and skin-directed treatment (ie, ultraviolet B phototherapy) on key markers of vascular disease risk compared with placebo in patients with psoriasis, an inflammatory disease well established to be associated with increased VI 10 , metabolic dysfunction, and an increased risk of cardiovascular disease and mortality. 3 TNF inhibitors are used in hundreds of thousands of patients with inflammatory bowel, joint, skin, and eye disease. Thus, our findings establish provocative information about their cardio- metabolic effects under rigorous experimental conditions in humans. Foremost, the study results strongly demonstrate that use of TNF inhibition has no impact, be it adverse, or ameliorative, on VI. Indeed, the 95% CI of our estimate in the open-label extension suggests we had adequate statistical power to exclude clinically significant alterations in VI from adalimumab considering statin effects as reference. 15 Our results are in line with a study that demonstrated no beneficial effects of TNF inhibition in patients with myocardial infarction, 22 however, they are in strong contrast to a noncontrolled study in rheumatoid arthritis of anti-TNF treatment which observed a reduction in VI by 18 F-FDG PET/CT after 8 weeks of therapy. 23 This study was open-label and assessed a reduction in the hottest plaque (most diseased aortic segment). We have also demonstrated improvements in VI in an observational study of psoriasis patients being treated systemically. 8, 24 Similarly, we observed a reduction in VI in the overall clinical trial population (comparing baseline to end of study), but this was because of improvements were seen in the period in which patients received placebo or phototherapy. Our patient reported outcomes suggest dietary improvements consistent with lifestyle changes advised by the American Heart Association 25 in the overall study population, which may in part explain the improvements in VI we observed that do not differentiate from placebo. These results emphasize the importance of randomization and placebo control in studies evaluating these highly sensitive outcomes. We propose several theories for the discrepancy between our experimental results evaluating VI, a surrogate marker of future cardiovascular events, and observational studies of actual cardiovascular events. 17, 26 It is possible that TNF associated benefits on cardiovascular events are mediated by pathways beyond VI such as thrombosis. 27 Moreover, large molecules (ie, antibodies) may not be directly active in large vessels such as the aorta because of impaired tissue penetration, which may explain why small molecules such as statins do have a strong anti-inflammatory effect on VI as early as after 4 weeks of treatment. 15 Psoriasis increasingly is recognized to be a Th17 driven disease, 7 and thus more targeted treatments may be necessary to alter VI in this specific patient population. We observed adverse impacts of adalimumab on key mediators of lipid metabolism such as cholesterol efflux capacity, which is a validated surrogate marker for the ability of HDL to perform reverse cholesterol transport, and HDL-P with no evidence of change in LDL-particle number. In contrast, we demonstrated strong and consistent improvements in skin inflammation (ie, clearance of psoriasis) and strong reductions in systemic inflammation as measured by serum TNF-α, CRP, and GlycA with short and longer-term adalimumab treatment but an increase in IL-6. It is, therefore, possible that anti-inflammatory benefits of adalimumab may be counteracted by adverse impacts on advanced measures of HDL structure and function resulting in a neutral effect on VI.
Although CRP, IL-6, TNF-α are established markers of cardiovascular disease, 12 GlycA is an emerging novel biomarker of systemic inflammation and cardiovascular disease derived from nuclear magnetic resonance, with value in psoriasis. 8, 11 It may be possible that the improvement in inflammatory biomarkers including GlycA seen in our study over a short-term follow-up may partially explain the observational evidence that has demonstrated better cardiovascular outcomes in psoriasis patients treated with anti-TNF therapy. 17 We observed a disconnect between changes in serum inflammatory markers and VI which was reported in a previous study. 28 Indeed, anti-TNF therapy has been associated with a decrease in systemic inflammatory markers 28 and future cardiovascular events in claims database studies. 17 However, in the short term, anti-TNF therapy has been shown to lead to an apolipoprotein B shift whereby LDL and triglycerides increase after initiation of therapy. Furthermore, IL-6 levels increased after anti-TNF treatment. Therefore, it may be possible that potential beneficial effects of anti-TNF therapy on VI were offset by the proatherogenic shift in lipoproteins and IL-6. It may also be possible that this younger group of patients included in our study had changes in biomarkers with less profound impact compared with statin studies which included older adults with more advanced atherosclerosis. Furthermore, other vascular beds including the coronary arteries may have changed coincident to biomarker changes but were not assessed in this study. Additionally, although there is early data for the use of FDG to evaluate treatment change, 15, 29 untoward effects of various kinds of treatment on FDG quantification require exploration. Finally, after adalimumab or phototherapy, we did not observe any change in glucose levels or insulin resistance by homeostasis model assessment of insulin resistance nor in adiponectin or leptin. It is entirely possible that homeostasis model assessment of insulin resistance, which detects peripheral skeletal muscle insulin resistance, but not CRP indicates C-reactive protein; GlycA, glycoprotein acetylation; HDL-P, high-density lipoprotein particle; IL, interleukin; LDL-P, low-density lipoprotein particle; TC, total cholesterol; and TNF, tumor necrosis factor.
*Difference of differences. †Global difference. ‡Statistically significant findings.
hepatic insulin resistance did not change because insulin resistance was not affected in the skeletal muscle. Future research should consider the assessment of clamp studies to understand whether hepatic insulin resistance improves. Our results are similar to a contemporaneous placebo-controlled trial of adalimumab on VI in psoriasis 30 which showed no evidence of change in VI in the aorta assessed by 18 F-FDG PET/CT, albeit the specified trial showed an increase in VI in the carotids. Furthermore, our inclusion of a phototherapy arm provides us with a unique opportunity to analyze the effect of biological treatment in relation to an established skin-directed treatment modality on cardiovascular and inflammatory markers, compared with placebo. Additionally, although the previous study only explored the impact of anti-TNF therapy on VI and assessed the baseline association between a few biomarkers and VI as well as psoriasis severity, we provide a more comprehensive assessment of indices of subclinical and clinical atherosclerosis by demonstrating modulation of contemporary inflammatory, cardiometabolic, and lipoprotein biomarkers compared with more standard markers assessed in the prior study.
Despite being randomized and placebo-controlled, our study has important limitations that warrant mention. First, though we had >80% power per our sample size calculations based on the primary outcome, our sample size was still relatively small, and our follow-up duration relatively short for cardiovascular disease study. As such, our results should be interpreted with certain caution, and future trials should consider employment of longer-duration follow-ups with expanded vascular outcomes, such as coronary CT angiography, to further test our findings. Our use of surrogate outcomes instead of hard cardiovascular end points limits our ability to derive definite conclusions. Furthermore, because phototherapy arm cannot be blinded, our comparisons between adalimumab and phototherapy arms in relation to placebo arm are subject to participant bias and as such our results should be interpreted with caution. The subset of 61 patients who participated in the openlabel extension period provided critical 1-year data suggesting no significant benefit of anti-TNF in reducing VI >1-year despite changes in biomarkers. However, one-fourth of the patients did not make it to 1-year of adalimumab treatment, and therefore these results should be interpreted with caution. The main reason for dropout was a failure of treatment response in the skin, and therefore, our findings in the extension study may overestimate benefits of adalimumab. Finally, we did not evaluate VI in carotid arteries, which in some studies was suggested to be more sensitive to change, 29 however, a large body of literature has focused on VI in the aorta as a surrogate for atherosclerosis and overall cardiovascular disease risk. 14, 31 In summary, our study demonstrates that anti-TNF therapy has strong and consistent anti-inflammatory effects in the skin and blood of patients with psoriasis in contrast to phototherapy, whereas both anti-TNF therapy and phototherapy had no impact on VI as assessed by 18 F-FDG PET/CT compared with placebo. Furthermore, anti-TNF therapy had no impact on glucose metabolism with potentially adverse effects on reverse cholesterol transport (a function of HDL) and HDL-particle size. These findings have important implications for our understanding of the relationship between targeted inhibition of TNF in a rigorous experimental trial of humans and its effect on cardiometabolic biomarkers and biomarkers of systemic and VI. Future experimental study is ongoing to determine the impact of biologics that target IL-12/23 and IL-17 as well as a small molecule (apremilast) that targets Phosphodiesterase 4 on pathways interrogated in the current study. Each of these therapies carries with it a highly specific potential effect on both systemic inflammation and cardio- metabolic diseases, thereby providing critically needed human data to understand other pathways at play in atherogenesis that result in premature morbidity and mortality in hundreds of millions of people worldwide.
